Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q2 2025 Earnings Presentation
16 slides from Vitrolife Ab's earnings presentation, Jul 17, 2025
Slide 1: ty REPRODU
ty REPRODU $ y) ee
Slide 2: Second quarter 2025
Second quarter 2025 Bronwyn Brophy O’Connor, CEO Helena Wennerström, Acting CFO Vitrolife AB (publ) 2025-07-17 2
Slide 3: Q2 /2025 Highlights
Q2 /2025 Highlights Q1 /2025 Highlights Growth Consumables Americas Strengthened Lead investor +1%* +9%* +9%* +5%** organizational in structure AutoIVF * Organic growth in local currencies excluding discontinued business 3 **Organic growth in local currencies
Slide 4: Strong performance across Consumables
Strong performance across Consumables Second quarter 2025 Sales Organic growth in local currencies Gross margin 871 MSEK excluding discontinued business 58.0% (941 MSEK) -7% in SEK +3% (59.9%) impacted by -8% due to currency 0% in local currencies EBITDA Operating cash flow Earnings per share 243 MSE
Slide 5: Currency headwinds accelerate in Q2 2025
Currency headwinds accelerate in Q2 2025 Vitrolife Group top 5 currencies, Illustrative picture currency development YTD Currency, development H1 2025 Vitrolife Group’s translation exposure risk is attributable to net investments in foreign operations. Assets and liabilities are translated at the cl
Slide 6: Sales and growth per geographical segment
Sales and growth per geographical segment Americas EMEA APAC Total Organic growth* excluding discontinued +5% +5% 0% +3% business Organic growth* +5% -3% 0% 0% Sales (MSEK) 295 326 250 871 Share of total sales 34% 37% 29% 6 * in local currencies
Slide 7: Market region EMEA
Market region EMEA -8% Total growth, impacted by -5% currency and by -8% discontinued business Net sales, MSEK 383 Organic growth 345 355 334 +5%* 328 326 311 310 -3%** • Sales in Consumables, +17% in local currencies (excl. discontinued business), taking share across the portfolio in all markets. •
Slide 8: Market region Americas
Market region Americas -6% Total growth, impacted by -11% currency Net sales, MSEK 316 311 Organic growth* 285 287 273 295 +5% 270 248 • A significant drop in cycles following the US IVF Executive Order signed in February. • Exceptionally strong comparable quarter last year for Technologies due to pu
Slide 9: Market region APAC
Market region APAC -8% Total growth, impacted by -7% currency Net sales, MSEK 283 Organic growth* 272 252 270 266 265 250 0% 238 • Cycles have not returned to pre-dragon levels in China, although we did see strong growth in Southeast Asia. • Consumables performing well due to share gains from compet
Slide 10: Geographical segments
Geographical segments Americas EMEA APAC Total Sales (MSEK) 295 326 250 871 Gross income (MSEK) 160 195 150 505 Gross margin % 54.2% 59.9% 59.8% 58.0% Selling expenses (MSEK) -75 -81 -47 -203 Market contribution (MSEK) 86 114 102 302 Contribution margin % 29.0% 35.0% 41.0% 34.7% Contribution margin
Slide 11: Q2 financial highlights
Q2 financial highlights Net sales of SEK 871 million (941), MSEK -7% in SEK 941 • Organic growth in local currencies +0% 871 -7% • Currency effect -8% • Organic growth in local currencies excluding discontinued business +3% 564 Gross income of SEK 505 million (564) 505 • Margin of 58.0% (59.9%) • Neg
Slide 12: Operating expenses
Operating expenses MSEK +6% 368 347 Operating expenses • Investment in Sales and Marketing in the US to take share in the largest IVF market as 203 previously announced. 196 • Increased administrative expenses driven by ongoing activities. • Other operating expenses increased due to foreign exchange
Slide 13: Key financials
Key financials 2025 2024 2025 2024 MSEK* April-June April-June January-June January-June Sales 871 941 1,714 1,782 Gross Margin, % 58.0 59.9 57.7 58.6 EBITDA 243 327 500 600 EBITDA Margin, % 27.8 34.7 29.2 33.6 Net income 100 143 199 258 EPS, SEK 0.74 1.06 1.48 1.91 Signed a 300 MEUR Operating cash fl
Slide 14: Focus for 2025
Focus for 2025 1. Continue to drive share gain in key markets leveraging the full breadth of the portfolio. Growth 2. Accelerate penetration of our combined EmbryoScope and lab control solutions. 3. Deliver best in class quality and customer service to further differentiate from competitors. 1. Prio
Slide 15: Q&A
Q&A Contact: investors@vitrolife.com
Slide 16: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there